EGFR and non-small cell lung carcinoma: This study evaluated the role of dynamic cfDNA level based on a large-panel NGS with 425 genes in predicting outcomes and identifying possible resistant mutations in EGFR T790M-positive NSCLC patients who received the third-generation EGFR TKIs.